1. Home
  2. LXRX vs PRAA Comparison

LXRX vs PRAA Comparison

Compare LXRX & PRAA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • LXRX
  • PRAA
  • Stock Information
  • Founded
  • LXRX 1995
  • PRAA 1996
  • Country
  • LXRX United States
  • PRAA United States
  • Employees
  • LXRX N/A
  • PRAA N/A
  • Industry
  • LXRX Biotechnology: Pharmaceutical Preparations
  • PRAA Finance: Consumer Services
  • Sector
  • LXRX Health Care
  • PRAA Finance
  • Exchange
  • LXRX Nasdaq
  • PRAA Nasdaq
  • Market Cap
  • LXRX 552.4M
  • PRAA 536.5M
  • IPO Year
  • LXRX 2000
  • PRAA N/A
  • Fundamental
  • Price
  • LXRX $1.38
  • PRAA $13.71
  • Analyst Decision
  • LXRX Buy
  • PRAA Strong Buy
  • Analyst Count
  • LXRX 5
  • PRAA 3
  • Target Price
  • LXRX $3.23
  • PRAA $26.00
  • AVG Volume (30 Days)
  • LXRX 2.4M
  • PRAA 279.5K
  • Earning Date
  • LXRX 11-06-2025
  • PRAA 11-03-2025
  • Dividend Yield
  • LXRX N/A
  • PRAA N/A
  • EPS Growth
  • LXRX N/A
  • PRAA 2208.29
  • EPS
  • LXRX N/A
  • PRAA 2.32
  • Revenue
  • LXRX $58,432,000.00
  • PRAA $1,132,016,000.00
  • Revenue This Year
  • LXRX $66.55
  • PRAA $5.16
  • Revenue Next Year
  • LXRX N/A
  • PRAA $8.28
  • P/E Ratio
  • LXRX N/A
  • PRAA $5.91
  • Revenue Growth
  • LXRX 1504.83
  • PRAA 15.79
  • 52 Week Low
  • LXRX $0.28
  • PRAA $12.91
  • 52 Week High
  • LXRX $1.95
  • PRAA $25.43
  • Technical
  • Relative Strength Index (RSI)
  • LXRX 49.80
  • PRAA 38.36
  • Support Level
  • LXRX $1.30
  • PRAA $13.25
  • Resistance Level
  • LXRX $1.48
  • PRAA $14.98
  • Average True Range (ATR)
  • LXRX 0.07
  • PRAA 0.51
  • MACD
  • LXRX -0.02
  • PRAA 0.05
  • Stochastic Oscillator
  • LXRX 27.77
  • PRAA 26.59

About LXRX Lexicon Pharmaceuticals Inc.

Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development, and commercialization of pharmaceutical products for the treatment of human diseases. Some of its drug candidates are LX9211, an orally-delivered small molecule drug candidate, also developing LX9851, an orally-delivered small molecule drug candidate, as a treatment for obesity and associated cardiometabolic.

About PRAA PRA Group Inc.

PRA Group Inc is a leader in acquiring and collecting nonperforming loans. The company returns capital to banks and other creditors to help expand financial services for consumers in the Americas, Europe, and Australia. It is also engaged in providing fee-based services on class action claims recoveries in the United States. The company's portfolio segments include; Core, which is engaged in purchasing and collecting nonperforming loans, which the originators have not chosen not to pursue, and the Insolvency segment which is engaged in purchasing and collecting nonperforming loans where the customer is involved in a bankruptcy proceeding.

Share on Social Networks: